{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:51:49Z","timestamp":1790797909457,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Cervical cancer remains one of the leading causes of cancer-related deaths among women globally, with inflammation playing a significant role in its progression. The phenomenon of cytokine storm, characterized by an excessive and uncontrolled release of pro-inflammatory cytokines, has been identified as a critical factor driving the pathogenesis of cervical cancer. Cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-\u03b1), IL-1\u03b2, and IL-8 are implicated in enhancing tumor growth, immune evasion, and metastasis. This review aims to explore the mechanisms underlying cytokine storm in cervical cancer and its contribution to tumor progression, focusing on the role of inflammation in altering the tumor microenvironment and promoting metastatic spread. The cytokine storm in cervical cancer induces a series of molecular and cellular responses, including the activation of key signaling pathways such as Janus kinase\/signal transducer and activator of transcription (JAK\/STAT), nuclear factor-kappa B (NF-\u03baB), and mitogen-activated protein kinase (MAPK), that drive tumor cell survival, proliferation, and invasiveness. The excessive production of these inflammatory cytokines alters the immune landscape, contributing to immune suppression and promoting an environment conducive to cancer cell survival. This dysregulated immune response not only enhances tumor aggressiveness but also renders the tumor more resistant to conventional therapies, posing significant challenges for treatment.<\/jats:p>","DOI":"10.1097\/ms9.0000000000004352","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:00:23Z","timestamp":1763370023000},"page":"492-499","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Inflammation, immunity, and invasion: the pivotal role of cytokine storms in cervical carcinogenesis"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4538-0161","authenticated-orcid":false,"given":"Emmanuel Ifeanyi","family":"Obeagu","sequence":"first","affiliation":[{"name":"Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"R1-20260514","article-title":"From inflammation to invasion: neutrophils in cervical cancer pathogenesis","author":"Obeagu","year":"2024","journal-title":"Ann Med Surg"},{"key":"R2-20260514","first-page":"10\u201397","article-title":"Monocytes and cervical ripening: a narrative review of prolonged labor pathophysiology","volume":"87","author":"Obeagu","year":"2025","journal-title":"Ann Med Surg"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Global Health"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"394\u2013407","DOI":"10.1016\/S1470-2045(18)30836-2","article-title":"Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020\u201399: a modelling study","volume":"20","author":"Simms","year":"2019","journal-title":"Lancet Oncol"},{"key":"R5-20260514","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3390\/cancers15041333","article-title":"A comprehensive view of the cancer-immunity cycle (CIC) in HPV-mediated cervical cancer and prospects for emerging therapeutic opportunities","volume":"15","author":"Avila","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R6-20260514","doi-asserted-by":"crossref","first-page":"132\u201354","DOI":"10.1007\/s13337-022-00768-w","article-title":"Human papillomavirus and cervical cancer: an insight highlighting pathogenesis and targeting strategies","volume":"33","author":"Ojha","year":"2022","journal-title":"Virusdisease"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"ftz048","DOI":"10.1093\/femspd\/ftz048","article-title":"Association of human papillomavirus infection and inflammation in cervical cancer","volume":"77","author":"Hemmat","year":"2019","journal-title":"Pathog Dis"},{"key":"R9-20260514","doi-asserted-by":"crossref","first-page":"3851\u201364","DOI":"10.7314\/APJCP.2014.15.9.3851","article-title":"Role of cytokines in genesis, progression and prognosis of cervical cancer","volume":"15","author":"Paradkar","year":"2014","journal-title":"Asian Pacific J Cancer Prev"},{"key":"R10-20260514","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3390\/diagnostics12081910","article-title":"Pathogenic and prognostic roles of paraneoplastic leukocytosis in cervical cancer: can genomic-based targeted therapies have a role? A literature review and an emblematic case report","volume":"12","author":"Madeddu","year":"2022","journal-title":"Diagnostics"},{"key":"R11-20260514","doi-asserted-by":"crossref","first-page":"899208","DOI":"10.3389\/fphar.2022.899208","article-title":"Therapeutic effects of natural products on cervical cancer: based on inflammatory pathways","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"R12-20260514","doi-asserted-by":"crossref","first-page":"410\u201330","DOI":"10.1016\/j.omto.2021.07.006","article-title":"Prognostic and therapeutic TILs of cervical cancer \u2013 Current advances and future perspectives","volume":"22","author":"Tang","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"R13-20260514","doi-asserted-by":"crossref","first-page":"110907","DOI":"10.1016\/j.intimp.2023.110907","article-title":"Disfunction of communication among immune cells in minimal-deviation adenocarcinoma of the cervix as an immunotherapeutic opportunity","volume":"124","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"R14-20260514","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3390\/nu16152569","article-title":"Nature of the association between rheumatoid arthritis and cervical cancer and its potential therapeutic implications","volume":"16","author":"Gusakov","year":"2024","journal-title":"Nutrients"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R16-20260514","doi-asserted-by":"crossref","first-page":"4195\u2013204","DOI":"10.1007\/s00432-022-04331-4","article-title":"Dynamic changes of soluble HLA-G and cytokine plasma levels in cervical cancer patients: potential role in cancer progression and immunotherapy","volume":"149","author":"Xu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"R17-20260514","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/cells12030416","article-title":"The role of cytokines in epithelial\u2013mesenchymal transition in gynaecological cancers: a systematic review","volume":"12","author":"Ray","year":"2023","journal-title":"Cells"},{"key":"R18-20260514","doi-asserted-by":"crossref","first-page":"1451\u201359","DOI":"10.3892\/ijo.2015.3122","article-title":"Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial-mesenchymal transition","volume":"47","author":"So","year":"2015","journal-title":"Int J Oncol"},{"key":"R19-20260514","doi-asserted-by":"crossref","first-page":"28\u201341","DOI":"10.4103\/tcmj.tcmj_134_24","article-title":"An exploration of the natural and acquired immunological mechanisms to high-risk human papillomavirus infection and unmasking immune escape in cervical cancer: a concise synopsis","volume":"37","author":"Mohammed","year":"2025","journal-title":"Tzu Chi Med J"},{"key":"R20-20260514","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3389\/fonc.2018.00431","article-title":"The role of the extracellular matrix and its molecular and cellular regulators in cancer cell plasticity","volume":"8","author":"Poltavets","year":"2018","journal-title":"Front Oncol"},{"key":"R21-20260514","doi-asserted-by":"crossref","first-page":"e0231594","DOI":"10.1371\/journal.pone.0231594","article-title":"Computational analysis for identification of the extracellular matrix molecules involved in endometrial cancer progression","volume":"15","author":"Yadav","year":"2020","journal-title":"PloS One"},{"key":"R22-20260514","doi-asserted-by":"crossref","first-page":"175\u201388","DOI":"10.1016\/j.currproblcancer.2018.04.001","article-title":"Gearing up T-cell immunotherapy in cervical cancer","volume":"42","author":"Chauhan","year":"2018","journal-title":"Curr Probl Cancer"},{"key":"R23-20260514","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.3390\/jcm12185992","article-title":"Advances in targeted therapy for the treatment of cervical cancer","volume":"12","author":"Watkins","year":"2023","journal-title":"J Clin Med"},{"key":"R24-20260514","doi-asserted-by":"crossref","first-page":"692142","DOI":"10.3389\/fonc.2021.692142","article-title":"Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis","volume":"11","author":"Kartikasari","year":"2021","journal-title":"Front Oncol"},{"key":"R25-20260514","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.3390\/cancers14092178","article-title":"Cytokines: can cancer get the message?","volume":"14","author":"Morris","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R26-20260514","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3892\/ol.2024.14463","article-title":"Cytokine release syndrome induced by immune checkpoint inhibitor treatment for uterine cervical cancer recurrence: a case report","volume":"28","author":"Sekimata","year":"2024","journal-title":"Oncol Lett"},{"key":"R27-20260514","doi-asserted-by":"crossref","first-page":"1114042","DOI":"10.3389\/fonc.2023.1114042","article-title":"Tumor microenvironment promotes lymphatic metastasis of cervical cancer: its mechanisms and clinical implications","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"R28-20260514","doi-asserted-by":"crossref","first-page":"1\u20139","DOI":"10.1186\/s13578-020-00453-9","article-title":"Critical steps to tumor metastasis: alterations of tumor microenvironment and extracellular matrix in the formation of pre-metastatic and metastatic niche","volume":"10","author":"Zhuyan","year":"2020","journal-title":"Cell Biosci"},{"key":"R29-20260514","first-page":"190\u2013203","article-title":"The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy","volume":"14","author":"van Meir","year":"2014","journal-title":"Anti-Cancer Agents in Med Chem (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)"},{"key":"R30-20260514","doi-asserted-by":"crossref","first-page":"726909","DOI":"10.3389\/fimmu.2021.726909","article-title":"Regulation of inflammatory cytokine storms by mesenchymal stem cells","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"R31-20260514","doi-asserted-by":"crossref","first-page":"1877\u201384","DOI":"10.1007\/s00262-010-0914-1","article-title":"Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers","volume":"59","author":"Geller","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"R32-20260514","doi-asserted-by":"crossref","first-page":"10126","DOI":"10.3390\/ijms221810126","article-title":"Dark side of cancer therapy: cancer treatment-induced cardiopulmonary inflammation, fibrosis, and immune modulation","volume":"22","author":"Boopathi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R33-20260514","first-page":"100082","article-title":"Transparency in the reporting of Artificial Intelligence \u2013 the TITAN Guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:04:35Z","timestamp":1778749475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004352","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"2025-05-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}